Predominantly Extraaxial Astroblastoma: Imaging and Proton MR Spectroscopy Features

Total Page:16

File Type:pdf, Size:1020Kb

Predominantly Extraaxial Astroblastoma: Imaging and Proton MR Spectroscopy Features Predominantly Extraaxial Astroblastoma: Imaging and Proton MR Spectroscopy Features J. Jeffery Baka, Suresh C. Patel, Joseph R. Roebuck, and David 0. Hearshen Summary: The CT, angiographic, MR, and proton MR spectros­ solid nodule to the cyst wall. There was no visible calcifi­ copy findings in a case of astroblastoma, a rare neoplasm of cation or surrounding vasogenic edema. glial cell origin, are presented. Of particular interest is the Left vertebral angiography (Fig. 2A and B) demonstrated predominantly extraaxial location of the tumor. CT and MR a 3-cm tumor stain with neovascularity and arteriovenous demonstrated a complex mass consisting of a solid nodule and shunting in the left occipital region. The blood supply was a peripheral septated cystic component. The extraaxial nature of pial origin and derived from the posterior and middle of the mass was suggested on MR. temporal branches of the left posterior cerebral artery, which were draped around a large, avascular component Index terms: Brain neoplasms, computed tomography; Brain of the mass. neoplasms, magnetic resonance; Brain neoplasms, angiography; Magnetic resonance (MR) (Fig. 3A-C) indicated a prob­ Magnetic resonance, spectroscopy able extraaxial mass that was in contact with the superior aspect of the tentorium. The solid portion of the mass was Astroblastoma is a well known but uncommon hypointense to gray matter on T1-weighted spin-echo and tumor of glial origin ( 1) . Although astroblastic inversion recovery sequences and on proton density­ elements are occasionally identified in specimens weighted spin-echo images and became hyperintense on of glioblastoma and astrocytoma, particularly T2-weighted spin-echo images. Tumor vessels produced punctate signal voids. The signal intensity of the cystic those of the gemistocytic variety, pure astroblas­ component paralleled the cerebrospinal fluid on all pulse tomas are rare ( 1-3). A few series and case sequences. reports ( 1-7) have appeared in the neurosurgery, One-dimensional proton CH) chemical shift imaging pathology, and oncology literature. This report (CSl) was performed in the region of the tumor (Fig. 4A describes the imaging features of a rare presen­ and B). The spectra displayed an increased choline (Cho)­ tation of this uncommon tumor. to-phosphocreatine/creatine (PCr/Cr) ratio, decreased N­ acetyl aspartate (NAA), increased lactate/lipid, and in­ creased myo-inositol (Ins) in those voxels containing pri­ Case Report marily solid tumor, as compared with those containing primarily cyst and normal brain. A 20-year-old woman presented with a 1-month history Gross total resection of the mass was performed. At of sharp left-sided headaches severe enough to wake her surgery, the tumor appeared extraparenchymal and was from sleep. Her only other complaint was difficulty reading, easily separated from the underlying brain. The cyst wall primarily an interpretive problem rather than a visual one; was hypervascular, and the peripherally displaced vessels she stated that it took her an hour to read and comprehend seen on angiography were embedded in the cyst wall. The a single written page. Physical examination revealed a solid component of the tumor was adherent to the tento­ homonymous right superior quadrantanopsia. Her neuro­ rium. logic examination was otherwise normal. The frozen section diagnosis was "extraparenchymous Precontrast and postcontrast computed tomographic neoplasm, probably glial," although atypical meningioma (CT) scans of the brain (Fig. 1) revealed a 7 X 5-cm and hemangiopericytoma were also considered. The final complex left medial occipital mass. Its superomedial com­ pathologic diagnosis, however, was malignant astroblas­ ponent, adjacent to the falx and tentorium, consisted of a toma (Fig. 5). This was confirmed by positive immunoper­ 3-cm enhancing solid nodule, which was sharply demar­ oxidase staining of the neoplastic cells for glial fibrillary cated from the anterior, lateral, and posterior cystic com­ acidic protein, as well as by electron microscopy. Conti­ ponent of cerebrospinal fluid density. There was enhance­ nuity between the solid nodule and the underlying cortex ment of the cyst wall and of septations radiating from the was demonstrated on only one slide, on which the interface Received June 30, 1992; revision requested August 2 1, received September 14, and accepted September 30. Department of Diagnostic Radiology, K-3 Neuroradiology, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, Ml 48202. Address requests for reprints to J. Jeffery Baka, MD. AJNR 14:946-950, Jui/Aug 1993 0195-6108/ 93/ 1404-0946 © American Society of Neuroradiology 946 AJNR: 14, July/August 1993 EXTRAAXlAL ASTROBLASTOMA 947 specific neurologic symptoms ( 1 ,3). Slow growth of the tumor often produces a long history of symptoms prior to presentation, usually 1 to 6 months, but occasionally 2 to 4 years (1). The tumor is most often supratentorial and hemispheric ( 1), although examples have been reported in the cerebellum, brain stem, fourth ventricle, hypothalamus, and pineal region (1 ,6,9). They are often located in the superficial cortical and subcortical tissues (1 ,2), and exten­ sions into the subarachnoid space (5), leptome­ ninges (1 ,2,6), and dura (1) have been described. A predominantly extraparenchymal location ap­ pears to be unusual. Microscopic cortical involve­ ment, as demonstrated in the case presented here, precludes the diagnosis of a primary extra­ parenchymous glial tumor (2). Although most Fig. 1. Contrast-enhanced CT scan demonstrates a mixed astroblastomas are well circumscribed (1 ,2), small cystic and solid left-occipital-region mass. The extraaxial location areas of extension into adjacent neural paren­ of the mass is not readily appreciated. Note the enhancement of chyma can be found ( 1, 7), and poorly defined both the solid tumor nodule and the cyst wall and radiating and infiltrating tumors have been reported (4). septations. Also note the normal calcified pineal gland (the pineal gland is known to be a site of origin of astroblastomas). Lobulated solid tumors measuring from a few millimeters to 8 em are most common (1) , but between tumor and parenchyma was sharp, and no dural small and large cysts are frequent. One of 23 infiltration was seen. Tumor cells were present in the cyst cases reported by Bonnin and Rubinstein had wall and septations as well as in the solid nodule. extensive calcification ( 1) . Microscopically, the tumor consists of charac­ teristic perivascular tumor cells which, when seen Discussion in cross-section, produce a typical pseudorosette Astroblastoma is among the rarest of central pattern reminiscent of ependymoma (Fig. 5) and, nervous system neoplasms (7), representing when sectioned longitudinally, demonstrate a 0.45% of gliomas (8). Usually a tumor of children, papillary or pseudopapillary arrangement (1-7). adolescents, and young adults (1 ,2), it has been Intervascular cells are indistinguishable from the reported in a 67 -year-old patient (3). There is no perivascular cells but are rarified, as opposed to sex predilection (2). Patients present with non- the more compact arrangement of the intervas- Fig. 2. Anteroposterior (A) and lateral (B) views from a left vertebral angiogram demonstrate a moderately hypervascular so lid component of the tumor surrounded by a region of avas­ cularity. Cortical branches (arrows) of the left posterior cerebral artery drape over the avascular portion, suggesting an intraaxial les ion. A 948 BAKA AJNR: 14, July/ August 1993 A Fig. 3. A, T1-weighted spin-echo sagittal image (450/19 [TR / TE]), 8 , T1 -weighted inversion recovery axial image (1500/ 20, inversion time = 600) and, C, T2-weighted spin-echo axial image (2500/50) demonstrate solid and cystic components of the tumor. Note the relationship of the mass to the tentorium in (A), suggesting that the tumor is largely extraaxial. Radiating septa are seen extending from the solid central component to the cyst wall (B and C). cular cells in ependymoma (2), the tumor with mas are associated with a worse prognosis, char­ which astroblastoma is most often confused his­ acterized by one or more recurrences, often with tologically (2,5-7). The tumor cells typically stain increasing degrees of anaplasia as well as con­ positively for glial fibrillary acidic protein, which version to glioblastoma ( 1 ,2). is indicative of a tumor of glial origin (2,6,7, 10). Ultrastructural similarities have suggested to Papillary meningioma and metastatic papillary some that the astroblastoma is derived from the carcinoma can produce a similar histologic pic­ tanycyte, a cell that is intrinsic to the ependyma ture (7). Necrosis is present microscopically in of submammalian vertebrates, but that is also 70% of astroblastomas, regardless of tumor grade found among the ependymal cells of embryonic ( 1 ). and neonatal higher mammals, including humans The natural history of astroblastoma lies some­ (2, 10) . The cells are distinguished from typical where between that of astrocytoma and glioblas­ ependymocytes by long processes that extend to toma (2,3). Two distinct histologic subtypes occur the pial surface of the brain (11). The persistence (1 ,2). Low-grade astroblastomas are associated of tanycytes into adulthood has been demon­ with a favorable postoperative prognosis, with strated in the rodent brain (12); in humans and survival up to 20 years; high-grade astroblasto- other higher mammals, the tanycyte appears to AJNR: 14, July/ August 1993 EXTRAAXIAL ASTROBLASTOMA 949 ho PCr/Cr , ,~ \ ( ~A L;rip _)'~~ 1 6 '-y. J~~ I S ~ I - I ~ 1 3 ~ 1 2 ~ ' ~ 10 ' 2 ' ppm A B Fig. 4. A, voxels used for [1H]CSI. A 2 X 2 X 8-cm voxel was selected with a water-suppressed stimulated-echo acquisition mode sequence (2000/20, TM = 11). Phase encoding in the anteroposterior direction yielded seven 2 X 2 X 1-cm subvoxels labeled 10 through 16. The image corresponds to a 3-mm section through the middle of the stimulated-echo acquisition mode voxel and delineates regions occupied by cyst, solid tumor, and normal brain. Adjacent contiguous slices contain variable amounts of these materials and were used to estimate their relative amounts in each voxel.
Recommended publications
  • Neurofibromatosis Type 2 (NF2)
    International Journal of Molecular Sciences Review Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis Suha Bachir 1,† , Sanjit Shah 2,† , Scott Shapiro 3,†, Abigail Koehler 4, Abdelkader Mahammedi 5 , Ravi N. Samy 3, Mario Zuccarello 2, Elizabeth Schorry 1 and Soma Sengupta 4,* 1 Department of Genetics, Cincinnati Children’s Hospital, Cincinnati, OH 45229, USA; [email protected] (S.B.); [email protected] (E.S.) 2 Department of Neurosurgery, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (M.Z.) 3 Department of Otolaryngology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (R.N.S.) 4 Department of Neurology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] 5 Department of Radiology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] * Correspondence: [email protected] † These authors contributed equally. Abstract: Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary brain tumor; many NF2 patients suffer from multiple meningiomas. In NF2, patients have mutations in the NF2 gene, specifically with loss of function in a tumor-suppressor protein that has a number of synonymous names, including: Merlin, Neurofibromin 2, and schwannomin. Merlin is a 70 kDa protein that has 10 different isoforms. The Hippo Tumor Suppressor pathway is regulated upstream by Merlin. This pathway is critical in regulating cell proliferation and apoptosis, characteristics that are important for tumor progression.
    [Show full text]
  • Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1
    [CANCER RESEARCH 49, 6137-6143. November 1, 1989] Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1 Susan Preston-Martin,2 Wendy Mack, and Brian E. Henderson Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033 ABSTRACT views with proxy respondents, we were unable to include a large proportion of otherwise eligible cases because they were deceased or Detailed job histories and information about other suspected risk were too ill or impaired to participate in an interview. The Los Angeles factors were obtained during interviews with 272 men aged 25-69 with a County Cancer Surveillance Program identified the cases (26). All primary brain tumor first diagnosed during 1980-1984 and with 272 diagnoses had been microscopically confirmed. individually matched neighbor controls. Separate analyses were con A total of 478 patients were identified. The hospital and attending ducted for the 202 glioma pairs and the 70 meningioma pairs. Meningi- physician granted us permission to contact 396 (83%) patients. We oma, but not glioma, was related to having a serious head injury 20 or were unable to locate 22 patients, 38 chose not to participate, and 60 more years before diagnosis (odds ratio (OR) = 2.3; 95% confidence were aphasie or too ill to complete the interview. We interviewed 277 interval (CI) = 1.1-5.4), and a clear dose-response effect was observed patients (74% of the 374 patients contacted about the study or 58% of relating meningioma risk to number of serious head injuries (/' for trend the initial 478 patients).
    [Show full text]
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • Survival and Functional Outcome of Childhood Spinal Cord Low-Grade Gliomas
    J Neurosurg Pediatrics 4:000–000,254–261, 2009 Survival and functional outcome of childhood spinal cord low-grade gliomas Clinical article KATRIN SCHEINEMANN, M.D.,1 UTE BARTELS, M.D.,2 ANNIE HUANG, M.D., PH.D.,2 CYNTHIA HAWKINS, M.D., PH.D.,3 ABHAYA V. KULKARNI, M.D., PH.D.,4 ERIC BOUFFET, M.D.,2 AND URI TABORI, M.D.2 1Division of Hematology/Oncology, McMaster Children’s Hospital, Hamilton; and Divisions of 2Hematology/ Oncology, 3Pathology, and 4Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada Object. Intramedullary spinal cord low-grade gliomas (LGGs) are rare CNS neoplasms in pediatric patients, and there is little information on therapy for and outcome of these tumors in this population. Furthermore, most patient series combine adult and pediatric patients or high- and low-grade tumors, resulting in controversial data regarding optimal treatment of these children. To clarify these issues, the authors performed a regional population-based study of spinal cord LGGs in pediatric patients. Methods.$OOSHGLDWULFSDWLHQWVZLWK/**VWUHDWHGGXULQJWKH05LPDJLQJHUD ² ZHUHLGHQWLÀHGLQ the comprehensive database of the Hospital for Sick Children in Toronto. Data on demographics, pathology, treat- ment details, and outcomes were collected. Results. Spinal cord LGGs in pediatric patients constituted 29 (4.6%) of 635 LGGs. Epidemiological and clini- cal data in this cohort were different than in patients with other spinal tumors and strikingly similar to data from pediatric patients with intracranial LGGs. The authors observed an age peak at 2 years and a male predominance in patients with these tumors. Histological testing revealed a Grade I astrocytoma in 86% of tumors.
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • Astrocytoma: a Hormone-Sensitive Tumor?
    International Journal of Molecular Sciences Review Astrocytoma: A Hormone-Sensitive Tumor? Alex Hirtz 1, Fabien Rech 1,2,Hélène Dubois-Pot-Schneider 1 and Hélène Dumond 1,* 1 Université de Lorraine, CNRS, CRAN, F-54000 Nancy, France; [email protected] (A.H.); [email protected] (F.R.); [email protected] (H.D.-P.-S.) 2 Université de Lorraine, CHRU-Nancy, Service de Neurochirurgie, F-54000 Nancy, France * Correspondence: [email protected]; Tel.: +33-372746115 Received: 29 October 2020; Accepted: 27 November 2020; Published: 30 November 2020 Abstract: Astrocytomas and, in particular, their most severe form, glioblastoma, are the most aggressive primary brain tumors and those with the poorest vital prognosis. Standard treatment only slightly improves patient survival. Therefore, new therapies are needed. Very few risk factors have been clearly identified but many epidemiological studies have reported a higher incidence in men than women with a sex ratio of 1:4. Based on these observations, it has been proposed that the neurosteroids and especially the estrogens found in higher concentrations in women’s brains could, in part, explain this difference. Estrogens can bind to nuclear or membrane receptors and potentially stimulate many different interconnected signaling pathways. The study of these receptors is even more complex since many isoforms are produced from each estrogen receptor encoding gene through alternative promoter usage or splicing, with each of them potentially having a specific role in the cell. The purpose of this review is to discuss recent data supporting the involvement of steroids during gliomagenesis and to focus on the potential neuroprotective role as well as the mechanisms of action of estrogens in gliomas.
    [Show full text]
  • High-Grade Glioma/Glioblastoma Multiforme: Is There a Role for Photodynamic Therapy?
    S-31 Supplement High-Grade Glioma/Glioblastoma Multiforme: Is There a Role for Photodynamic Therapy? Presented by Harry T. Whelan, MD, Medical College of Wisconsin, Milwaukee, Wisconsin Abstract backward glance at the origins of PDT for brain tumors, In the United States, the 5-year survival rate for patients of all ages describes the clinical challenges to its use in the skull, with all types of brain tumors is approximately 20%, with the scale skewed toward even poorer survival in patients with gliomas. Al- and outlines the objectives of his phase I study for PDT though surgery and radiotherapy are primary treatment options, in children with brain cancer, the second most common surgery is rarely curative and radiotherapy has had little impact childhood cancer after leukemia. on overall survival. Predominantly studied in adults with advanced Gliomas are among the most challenging of brain high-grade gliomas, photodynamic therapy (PDT) represents tumor subtypes. The location of a benign tumor in the a paradigmatic shift in the treatment of brain tumors. With no eloquent areas of the brain could potentially render it clear standard of care for brain tumors, PDT may emerge as a po- tential alternative, although challenges regarding its clinical use inoperable, the presence of a blood–brain barrier limits remain and studies confirming its promise are necessary. JNCCN( the ability of systemically administered medications to 2012;10[Suppl 2]:S31–S34) reach the target site, and the intricate neuronal net- work makes targeted therapy challenging. Patients with high-grade gliomas (HGGs) in particular have a generally poor prognosis, and surgery is rarely curative.
    [Show full text]
  • Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: a Multicentric International Analysis
    cancers Article Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis Laith Samhouri 1,†, Mohamed A. M. Meheissen 2,3,† , Ahmad K. H. Ibrahimi 4, Abdelatif Al-Mousa 4, Momen Zeineddin 5, Yasser Elkerm 3,6, Zeyad M. A. Hassanein 2,3 , Abdelsalam Attia Ismail 2,3, Hazem Elmansy 3,6, Motasem M. Al-Hanaqta 7 , Omar A. AL-Azzam 8, Amr Abdelaziz Elsaid 2,3 , Christopher Kittel 1, Oliver Micke 9, Walter Stummer 10, Khaled Elsayad 1,*,‡ and Hans Theodor Eich 1,‡ 1 Department of Radiation Oncology, University Hospital Münster, Münster 48149, Germany; [email protected] (L.S.); [email protected] (C.K.); [email protected] (H.T.E.) 2 Alexandria Clinical Oncology Department, Alexandria University, Alexandria 21500, Egypt; [email protected] (M.A.M.M.); [email protected] (Z.M.A.H.); [email protected] (A.A.I.); [email protected] (A.A.E.) 3 Specialized Universal Network of Oncology (SUN), Alexandria 21500, Egypt; [email protected] (Y.E.); [email protected] (H.E.) 4 Department of Radiotherapy and Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan; [email protected] (A.K.H.I.); [email protected] (A.A.-M.) 5 Department of Pediatrics, King Hussein Cancer Center, Amman 11942, Jordan; [email protected] 6 Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria 21500, Egypt 7 Military Oncology Center, Royal Medical Services, Amman 11942, Jordan; [email protected] 8 Princess Iman Research Center, King Hussein Medical Center, Royal Medical Services, Amman 11942, Jordan; Citation: Samhouri, L.; Meheissen, [email protected] 9 M.A.M.; Ibrahimi, A.K.H.; Al-Mousa, Department of Radiotherapy and Radiation Oncology, Franziskus Hospital Bielefeld, A.; Zeineddin, M.; Elkerm, Y.; 33699 Bielefeld, Germany; [email protected] 10 Department of Neurosurgery, University Hospital Münster, 48149 Münster, Germany; Hassanein, Z.M.A.; Ismail, A.A.; [email protected] Elmansy, H.; Al-Hanaqta, M.M.; et al.
    [Show full text]
  • The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
    International Journal of Molecular Sciences Review The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy Fiona A. Desland and Adília Hormigo * Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Department of Neurology, Box 1137, 1 Gustave L. Levy Pl, New York, NY 10029-6574, USA; fi[email protected] * Correspondence: [email protected] Received: 28 August 2020; Accepted: 29 September 2020; Published: 5 October 2020 Abstract: Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor in adults. Its aggressive nature is attributed partly to its deeply invasive margins, its molecular and cellular heterogeneity, and uniquely tolerant site of origin—the brain. The immunosuppressive central nervous system (CNS) and GBM microenvironments are significant obstacles to generating an effective and long-lasting anti-tumoral response, as evidenced by this tumor’s reduced rate of treatment response and high probability of recurrence. Immunotherapy has revolutionized patients’ outcomes across many cancers and may open new avenues for patients with GBM. There is now a range of immunotherapeutic strategies being tested in patients with GBM that target both the innate and adaptive immune compartment. These strategies include antibodies that re-educate tumor macrophages, vaccines that introduce tumor-specific dendritic cells, checkpoint molecule inhibition, engineered T cells, and proteins that help T cells engage directly with tumor cells. Despite this, there is still much ground to be gained in improving the response rates of the various immunotherapies currently being trialed. Through historical and contemporary studies, we examine the fundamentals of CNS immunity that shape how to approach immune modulation in GBM, including the now revamped concept of CNS privilege.
    [Show full text]
  • Arrocase Spinal Glioma
    Spinal Cord Glioma Timothy Malouff, MD Faculty: Jennifer Peterson, MD Mayo Clinic Florida Jacksonville, FL February 19, 2020 Case • 22 year old female with no relevant PMH presented with a one month history of mid- back pain and a small area of numbness on her knee. • ROS: Positive for gradually progressive bilateral lower extremity weakness and paresthesia. – No bladder or bowel dysfunction. – No saddle anesthesia February 19, 2020 Case • SH: No previous surgeries • FH: No family history of cancer or neurologic disorders. • SH: Nonsmoker, no alcohol use, no drug use • Medications: None • Exam: 3/5 strength in the bilateral lower extremities, otherwise unremarkable February 19, 2020 Case • Given her continued progressive symptoms despite conservative treatment with physical therapy, an MRI was obtained February 19, 2020 Case • MR of the thoracic spine – T11-T12 centrally located intramedullary expanding lesion with well defined borders and mild heterogeneous enhancement – Radiographically consistent with ependymoma • MR of the brain, cervical spine, and lumbar spine were negative February 19, 2020 MRI T2 imaging: Centrally located mass with well defined borders Most consistent with ependymoma February 19, 2020 Workup (NCCN v3.2019) • Spine MRI (cervical, thoracic, and lumbar) • CT myelogram if MRI is contraindicated February 19, 2020 Treatment options (per NCCN) Observation Asymptomatic Maximum safe Well resection defined/circumscribed on MRI Maximum safe Symptomatic resection Intramedullary tumors Observation Asymptomatic Biopsy Poorly
    [Show full text]
  • Last Updated March 2020 NF1 Mutations: Neurofibromatosis Type 1
    Last Updated March 2020 NF1 Mutations: Neurofibromatosis Type 1 (NF1) Neurofibromatosis Type 1 (NF1) is a neurocutaneous condition with extremely variable clinical features that increase in frequency with age. Features include multiple cafe-au-lait spots (“birth marks”), axillary and inguinal freckling, Lisch nodules (benign tumors of the iris), optic gliomas, and cutaneous neurofibromas. While most of the tumors seen within NF1 are benign, they can cause complications that require management. Additionally, individuals with NF1 have an increased risk for various malignancies. NF1 Cancer/ Tumor Risks Neurofibromas: Nerve tumor that arise from the nerve sheath (cells surrounding the nerves). Cutaneous neurofibromas: Individuals with NF1 will usually develop multiple benign cutaneous or subcutaneous neurofibromas by adulthood. Though these are benign, but can be disfiguring. Plexiform neurofibromas: About 50% of people with NF1 will have plexiform neurofibromas, most of which occur internally and are not usually clinically apparent.1 Most plexiform neurofibromas are slow growing, but rapid growth can be life threatening or cause disfigurement. Malignant peripheral nerve sheath tumors (MPNST): Deeper subcutaneous and plexiform neurofibromas may undergo malignant change to MPNST in up to 16% of people with NF1.2,3 These tumors occur at younger ages and have poorer prognosis than in individuals without NF1 who have MPNST. Glioma/Central Nervous System (CNS) Tumors: Gliomas are tumors that arise from the glial cells that surround nerve cells. The most common tumors apart from benign neurofibromas in people with NF1 are optic nerve gliomas and brain tumors. The frequency of optic glioma is estimated to be between 5-25%.4 It is also estimated that 4% of individuals with NF1 will develop brainstem tumors.5 Approximately 20% of individuals with childhood optic glioma will develop subsequent CNS gliomas.
    [Show full text]
  • Perinatal (Fetal and Neonatal) Astrocytoma: a Review
    Childs Nerv Syst DOI 10.1007/s00381-016-3215-y REVIEW PAPER Perinatal (fetal and neonatal) astrocytoma: a review Hart Isaacs Jr.1,2 Received: 16 July 2016 /Accepted: 3 August 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Keywords Fetal astrocytoma . Neonatal astrocytoma . Introduction The purpose of this review is to document the Perinatal astrocytoma . Intracranial hemorrhage . Congenital various types of astrocytoma that occur in the fetus and neo- brain tumor nate, their locations, initial findings, pathology, and outcome. Data are presented that show which patients are likely to sur- vive or benefit from treatment compared with those who are Introduction unlikely to respond. Materials and methods One hundred one fetal and neonatal Glial cells are the supportive elements of the central nervous tumors were collected from the literature for study. system (CNS) [22]. They include astrocytes, oligodendro- Results Macrocephaly and an intracranial mass were the most cytes, and ependymal cells, and the corresponding tumors common initial findings. Overall, hydrocephalus and intracra- originating from these cells astrocytoma, oligodendroglioma, nial hemorrhage were next. Glioblastoma (GBM) was the and ependymoma all of which are loosely called Bglioma^ most common neoplasm followed in order by subependymal [16, 22]. The term Bglioma^ is used interchangeably with giant cell astrocytoma (SEGA), low-grade astrocytoma, ana- astrocytoma to describe the more common subgroup of tu- plastic astrocytoma, and desmoplastic infantile astrocytoma mors [22]. (DIA). Tumors were detected most often toward the end of Glioma (astrocytoma) is the leading CNS tumor in chil- the third trimester of pregnancy.
    [Show full text]